Results of a seven-year follow-up of an atypical form of multiple sclerosis, Marburg variant

Bibliography:
1 Vasuta VA. Management of risk factors for the development of optic nerve atrophy based on a systematic approach and comprehensive assessments. Vestnik of Vitebsk State Medical University 2015; 14 (3): 78–82
2 Prineas J. Pathology of multiple sclerosis. In: Cook S, ed. Handbook of Multiple Sclerosis. N. Y. : Marcel Dekker, 2011; p. 289–324
3 Popova EV, Bryukhov VV, Boyko AN. Atypical multiple sclerosis, a variant of Marburg: a clinical case and review. International Neurological Journal 2018; 2 (96): 76–81
4 Polman SCh, Reingold SC, Banwell B. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology 2011; 69 (2): 292–302. DOI: 10.1002 / ana. 22366
5 World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. URL: http://www.wma.ne t / en / 30publications / 10policies / b 3 / inde x. html
6 Ioyleva EE, Krivosheeva MS, Markova EYu. Modern technologies in the examination of patients with optic nerve atrophy due to multiple sclerosis. Ophthalmology 2018; 15 (2S): 246–53
7 Ioyleva EE, Andrusyakova EP, Safonenko AYu. Questions of neurodegeneration and demyelination in multiple sclerosis according to optical coherence tomography. Practical medicine 2018; 16 (4): 149–52
8 Masdeu J, Quinto C, Olivera C, et al. Open-ring imaging sign: Highly specifc for atypical brain demyelination Neurology 2000; 54 (7): 1427–33. DOI: 10.1212 / wnl. 54.7.1427
9 Jefery D, Lefkowitz D, Crittenden J. Treatment of Marburg Variant Multiple Sclerosis with Mitoxantrone. Journal of Neuroim-aging 2004; 14 (1): 58–62. DOI: 10.1177 / 1051228403259393